Xuede Lin, Ph.D. - Publications
Affiliations: | 2008 | University of Nebraska Medical Center, Omaha, NE, United States |
Area:
ImmunologyYear | Citation | Score | |||
---|---|---|---|---|---|
2009 | Lin X, Wang X, Capek HL, Simone LC, Tuli A, Morris CR, Reber AJ, Solheim JC. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines. Cancer Immunology, Immunotherapy : Cii. 58: 729-36. PMID 18828016 DOI: 10.1007/S00262-008-0595-1 | 0.599 | |||
2007 | Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, Sadanandam A, Suleiman K, Singh RK, Talmadge JE, Solheim JC. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biology & Therapy. 6: 1206-10. PMID 17617742 DOI: 10.4161/Cbt.6.8.4405 | 0.62 | |||
2007 | Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biotherapy & Radiopharmaceuticals. 22: 235-8. PMID 17600470 DOI: 10.1089/Cbr.2007.336 | 0.685 | |||
2007 | Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. International Journal of Oncology. 30: 631-9. PMID 17273764 DOI: 10.3892/Ijo.30.3.631 | 0.709 | |||
Show low-probability matches. |